These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

454 related items for PubMed ID: 31340760

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Sustained responses to lasmiditan: Results from post-hoc analyses of two Phase 3 randomized clinical trials for acute treatment of migraine.
    Doty EG, Krege JH, Jin L, Raskin J, Halker Singh RB, Kalidas K.
    Cephalalgia; 2019 Oct; 39(12):1569-1576. PubMed ID: 31266353
    [Abstract] [Full Text] [Related]

  • 4. Onset of Efficacy Following Oral Treatment With Lasmiditan for the Acute Treatment of Migraine: Integrated Results From 2 Randomized Double-Blind Placebo-Controlled Phase 3 Clinical Studies.
    Ashina M, Vasudeva R, Jin L, Lombard L, Gray E, Doty EG, Yunes-Medina L, Kinchen KS, Tassorelli C.
    Headache; 2019 Nov; 59(10):1788-1801. PubMed ID: 31529622
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Tolerability and Safety of Lasmiditan Treatment in Elderly Patients With Migraine: Post Hoc Analyses From Randomized Studies.
    Martin VT, Ahmed Z, Hochstetler HM, Baygani SK, Dong Y, Hauck PM, Khanna R.
    Clin Ther; 2021 Jun; 43(6):1066-1078. PubMed ID: 34366152
    [Abstract] [Full Text] [Related]

  • 7. Effect of a change in lasmiditan dose on efficacy and safety in patients with migraine.
    Clemow DB, Hochstetler HM, Dong Y, Hauck P, Peres MFP, Ailani J.
    Postgrad Med; 2021 May; 133(4):449-459. PubMed ID: 33730977
    [Abstract] [Full Text] [Related]

  • 8. Lasmiditan in patients with common migraine comorbidities: a post hoc efficacy and safety analysis of two phase 3 randomized clinical trials.
    Clemow DB, Baygani SK, Hauck PM, Hultman CB.
    Curr Med Res Opin; 2020 Nov; 36(11):1791-1806. PubMed ID: 32783644
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Lasmiditan for the acute treatment of migraine: Subgroup analyses by prior response to triptans.
    Knievel K, Buchanan AS, Lombard L, Baygani S, Raskin J, Krege JH, Loo LS, Komori M, Tobin J.
    Cephalalgia; 2020 Jan; 40(1):19-27. PubMed ID: 31744319
    [Abstract] [Full Text] [Related]

  • 11. A close association of freedom from pain, migraine-related functional disability, and other outcomes: results of a post hoc analysis of randomized lasmiditan studies SAMURAI and SPARTAN.
    Lipton RB, Baygani SK, Tepper SJ, Krege JH, Vasudeva R, Pearlman EM, Hauck PM, Loo LS.
    J Headache Pain; 2021 Aug 28; 22(1):101. PubMed ID: 34454420
    [Abstract] [Full Text] [Related]

  • 12. Safety findings from Phase 3 lasmiditan studies for acute treatment of migraine: Results from SAMURAI and SPARTAN.
    Krege JH, Rizzoli PB, Liffick E, Doty EG, Dowsett SA, Wang J, Buchanan AS.
    Cephalalgia; 2019 Jul 28; 39(8):957-966. PubMed ID: 31166697
    [Abstract] [Full Text] [Related]

  • 13. Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine.
    Goadsby PJ, Wietecha LA, Dennehy EB, Kuca B, Case MG, Aurora SK, Gaul C.
    Brain; 2019 Jul 01; 142(7):1894-1904. PubMed ID: 31132795
    [Abstract] [Full Text] [Related]

  • 14. Characterization of Dizziness After Lasmiditan Usage: Findings From the SAMURAI and SPARTAN Acute Migraine Treatment Randomized Trials.
    Tepper SJ, Krege JH, Lombard L, Asafu-Adjei JK, Dowsett SA, Raskin J, Buchanan AS, Friedman DI.
    Headache; 2019 Jul 01; 59(7):1052-1062. PubMed ID: 31152441
    [Abstract] [Full Text] [Related]

  • 15. Phase 2 randomized placebo-controlled study of lasmiditan for the acute treatment of migraine in Japanese patients.
    Sakai F, Takeshima T, Homma G, Tanji Y, Katagiri H, Komori M.
    Headache; 2021 May 01; 61(5):755-765. PubMed ID: 33990951
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Improvement in Function after Lasmiditan Treatment: Post Hoc Analysis of Data from Phase 3 Studies.
    Smith T, Krege JH, Rathmann SS, Dowsett SA, Hake A, Nery ESM, Matthews BR, Doty EG.
    Neurol Ther; 2020 Dec 01; 9(2):459-471. PubMed ID: 32447545
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.